{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:45Z","timestamp":1793120205084,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) has a growing global prevalence, and the need for safe and effective treatments is urgent. Donepezil is commonly used therapeutic agents for AD but has safety controversies. The objective of this study was to thoroughly evaluate donepezil\u2019s adverse event profile using actual data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, reports of donepezil-related adverse events were collected from the first quarter of 2004 to the fourth quarter of 2024 through the FAERS database. The association of donepezil-induced adverse events was disproportionality analyzed using Reporting odds Ratios (ROR) and Proportional Reporting Ratio (PRR) and Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-item Gamma Poisson Shrinker (MGPS), among other methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 26,120 ADRs with donepezil as the \u201cfirst suspect\u201d were retrieved during the reporting period. The most common AEs included nausea, vomiting, syncope, and dizziness, which were consistent with the labeling of the medication and clinical trials. Unintended major AEs such as fall, hypotension, tremor, cognitive disorder, mania, and the highest signal of pleurothotonus were also detected. The reports also collected were characterized by a high proportion of female patients (51.3%) and the time of AE induction within 30\u202fdays (41%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Donepezil treatment needs to focus on cardiovascular and neurological adverse events, especially for women, elderly patients, or patients with co-morbidities, cardiac monitoring and dose adjustment should be strengthened. Clinics need to balance efficacy and risk, develop individualized dosing regimens, and explore novel therapeutic strategies to improve long-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1655216","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:05:36Z","timestamp":1765371936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/ijms24010107","article-title":"Pathogenesis of Alzheimer's disease","volume":"24","author":"Rostagno","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.arr.2024.102199","article-title":"Recent trends in treatment strategies for Alzheimer(')s disease and the challenges: a topical advancement","volume":"94","author":"Liu","year":"2024","journal-title":"Ageing Res Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.1380","article-title":"2020 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/18715273113126660166","article-title":"Current acetylcholinesterase-inhibitors: a neuroinformatics perspective","volume":"13","author":"Shaikh","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3892\/mmr.2019.10374","article-title":"Cholinesterase inhibitors as Alzheimer's therapeutics (review)","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol Med Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1343650","DOI":"10.3389\/fphar.2023.1343650","article-title":"Cholinesterase inhibitors-associated torsade de pointes\/QT prolongation: a real-world pharmacovigilance study","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/JAD-201551","article-title":"Bradycardia due to donepezil in adults: systematic analysis of FDA adverse event reporting system","volume":"81","author":"Morris","year":"2021","journal-title":"J Alzheimer's Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin Drug Investig"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US Food and Drug Administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","article-title":"Guidelines for submitting adverse event reports for publication","volume":"30","author":"Kelly","year":"2007","journal-title":"Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1290975","DOI":"10.3389\/fphar.2024.1290975","article-title":"A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref19","year":""},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","article-title":"Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"CD001190","DOI":"10.1002\/14651858.CD001190.pub3","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/j.1532-5415.2009.02488.x","article-title":"Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system","volume":"57","author":"Hernandez","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4062\/biomolther.2017.189","article-title":"The effects of donepezil, an acetylcholinesterase inhibitor, on impaired learning and memory in rodents","volume":"26","author":"Shin","year":"2018","journal-title":"Biomol Ther (Seoul)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12012-019-09543-8","article-title":"Proarrhythmic effect of acetylcholine-esterase inhibitors used in the treatment of Alzheimer's disease: benefit of rivastigmine in an experimental whole-heart model","volume":"20","author":"Ellermann","year":"2020","journal-title":"Cardiovasc Toxicol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.parkreldis.2006.03.010","article-title":"Pisa syndrome as a motor complication of Parkinson's disease","volume":"13","author":"Kim","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/geriatrics9040100","article-title":"Pisa syndrome secondary to drugs: a scope review","volume":"9","author":"Pitton Rissardo","year":"2024","journal-title":"Geriatrics (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/WNF.0000000000000500","article-title":"Brexpiprazole-associated Pisa syndrome (Pleurothotonus) in a patient with dementia","volume":"45","author":"Nagai","year":"2022","journal-title":"Clin Neuropharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Alzheimer's","year":"2016","journal-title":"Alzheimers Dement"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1212\/WNL.0000000000004425","article-title":"Sex differences in Alzheimer risk: brain imaging of endocrine vs chronologic aging","volume":"89","author":"Mosconi","year":"2017","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1755-5949.2010.00189.x","article-title":"Genomics and pharmacogenomics of dementia","volume":"17","author":"Cacabelos","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","article-title":"Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes","volume":"56","author":"Sink","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"ref33","first-page":"CD001190","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"3","author":"Birks","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.genm.2008.05.005","article-title":"Drug-induced long QT syndrome in women: review of current evidence and remaining gaps","volume":"5","author":"Hreiche","year":"2008","journal-title":"Gend Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","article-title":"Gender differences in adverse drug reactions: analysis of spontaneous reports to a regional pharmacovigilance centre in France","volume":"16","author":"Montastruc","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s10072-022-06586-8","article-title":"Anti-dementia drugs: a descriptive study of the prescription pattern in Italy","volume":"44","author":"Ippoliti","year":"2023","journal-title":"Neurol Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.18553\/jmcp.2008.14.S6-A.2","article-title":"Gender differences in health care expenditures, resource utilization, and quality of care","volume":"14","author":"Owens","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study","volume":"169","author":"Gill","year":"2009","journal-title":"Arch Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1691\/ph.2023.2584","article-title":"Adverse drug event profile associated with anti-dementia drugs: analysis of a spontaneous reporting database","volume":"78","author":"Kose","year":"2023","journal-title":"Pharmazie"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/jamaneurol.2017.0643","article-title":"Association of dual-task gait with incident dementia in mild cognitive impairment: results from the gait and brain study","volume":"74","author":"Montero-Odasso","year":"2017","journal-title":"JAMA Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/TCRM.S323387","article-title":"Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review","volume":"17","author":"Ruangritchankul","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"ref43","first-page":"31","article-title":"Pisa syndrome secondary to rivastigmine: a case report","volume":"163","author":"Leelavathi","year":"2012","journal-title":"Clin Ter"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/WAD.0b013e318215ca90","article-title":"Falls and risk factors for falls in community-dwelling adults with dementia (NutriAlz trial)","volume":"26","author":"Salv\u00e0","year":"2012","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin Drug Saf"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1655216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:05:37Z","timestamp":1765371937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1655216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":45,"alternative-id":["10.3389\/fneur.2025.1655216"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1655216","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1655216"}}